NU223612 是一种有效的 PROTAC,可降解吲哚胺 2,3-双加氧酶 1 (IDO1)(Indoleamine 2,3-Dioxygenase (IDO)),Kd 为 640 nM,它通过 CRBN 介导的蛋白酶体降解有效降解 IDO1 蛋白,以 290 nM 的亲和力与 CRBN 结合,并可穿过血脑屏障 (BBB)。
产品编号: MS-H89854 纯度: 99.41% CAS No.: 2759420-43-2 分子式: C49H55FN6O9 分子量: 890.99
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

NU223612 是一种有效的 PROTAC,可降解吲哚胺 2,3-双加氧酶 1 (IDO1)(Indoleamine 2,3-Dioxygenase (IDO)),Kd 为 640 nM,它通过 CRBN 介导的蛋白酶体降解有效降解 IDO1 蛋白,以 290 nM 的亲和力与 CRBN 结合,并可穿过血脑屏障 (BBB)。

生物实验数据

生物活性 NU223612 is a potent PROTAC that degrades indoleamine 2,3-dioxygenase 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)) with a Kd of 640 nM, effectively degrading IDO1 protein via CRBN-mediated proteasomal degradation, binding to CRBN with an affinity of 290 nM, and penetrating the blood-brain barrier (BBB).
IC50 & Target IDO1:640 nM (Kd)
体外研究
(In Vitro)

NU223612 (0.1-10 μM; 24 h) decreases IDO1 protein levels dose-dependently.
A DC50 (the concentration of the NU223612 at which 50% of the IDO1 protein is degraded) of 0.3290 μM and 0.5438 μM in U87 and GBM43 cells is determined, respectively.
NU223612 degrades IDO1 protein in multiple cell types, such as CD18 and PANC-1 human pancreatic cancer cells, OVCAR5 and SKOV3 human ovarian cancer cells, PC3 human prostate cancer cells, and the syngeneic GL261 mouse IDO1 cDNA-expressing (IDO1-O/E) glioma cell line.
NU223612 equally degrades IDO1 protein levels in both the cytoplasmic and nuclear intracellular compartments in human GBM cells. NU223612 is able to penetrate subcellular compartments.
NU223612 dose-dependently inhibits IDO1 enzyme activity resulting in decreased Kyn levels in cultured IFNγ-stimulated GBM cells. NU223612 inhibits both IDO1-mediated tryptophan metabolism as well as IDO1 non-enzyme-mediated NF-κB p65 transcription factor DNA binding activity.

Western Blot Analysis

Cell Line: U87 and human GBM43 cells
Concentration: 0 μM, 0.1 μM, 1 μM, and 10 μM
Incubation Time: 24 h
Result: Decreased IDO1 protein levels dose-dependently.
体内研究
(In Vivo)

NU223612 (25 mg/kg; i.p.; once) decreases IDO1 protein in C57BL/6 with mIDO1 cDNA-expressing GL261 cells.
NU223612 (25 mg/kg; i.p.; 5 days/week; for 3 weeks) leads to an increase in median overall survival as well as longer-term survival for up to 45 days post-tumor cell injection.
Mass spectrometry analysis of NU223612 (25 mg/kg; i.p.; once) shows a Cmax of 2 μM and a half-life of 8.3 h in brain tissue. In plasma, Cmax is 365 μM and the half-life is 2.5 h. The binding of NU223612 to mouse brain homogenate using a 6 h equilibrium dialysis shows NU223612 to be 99.8% bound.
Half-life, AUC, and Cmax of NU223612 in serum and brain samples.

Plasma Brain
half-lifr (h) 2.5 8.3
AUC0-24 (μM h) 582 7
Cmax (μM) 365 2

Animal Model: Male C57BL/6 mice bearing GL261 cells
Dosage: 25 mg/kg
Administration: i.p.; once
Result: Decreased IDO1 protein by >70% within 2 h post-treatment and remains low for up to 24 h.
Animal Model: 8 week old C57BL/6 wild-type (WT) mice are intracranially engrafted with luciferase-modified GL261 cells (GL261-luc.)
Dosage: 25 mg/kg
Administration: i.p.; 5 days/week; for 3 weeks
Result: Led to an increase in median overall survival as well as longer-term survival for up to 45 days post-tumor cell injection.
性状 固体
颜色 White to yellow

化学信息

分子量 890.99
分子式 C49H55FN6O9
CAS No. 2759420-43-2

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (112.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.1223 mL5.6117 mL11.2235 mL28.0587 mL
5 mM0.2245 mL1.1223 mL2.2447 mL5.6117 mL
10 mM0.1122 mL0.5612 mL1.1223 mL2.8059 mL
15 mM0.0748 mL0.3741 mL0.7482 mL1.8706 mL
20 mM0.0561 mL0.2806 mL0.5612 mL1.4029 mL
25 mM0.0449 mL0.2245 mL0.4489 mL1.1223 mL
30 mM0.0374 mL0.1871 mL0.3741 mL0.9353 mL
40 mM0.0281 mL0.1403 mL0.2806 mL0.7015 mL
50 mM0.0224 mL0.1122 mL0.2245 mL0.5612 mL
60 mM0.0187 mL0.0935 mL0.1871 mL0.4676 mL
80 mM0.0140 mL0.0701 mL0.1403 mL0.3507 mL
100 mM0.0112 mL0.0561 mL0.1122 mL0.2806 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础